ACR–ACNM–SNMMI–SPR PRACTICE PARAMETER FOR THE PERFORMANCE OF NEUROENDOCRINE TUMOR SCINTIGRAPHY

PREAMBLE

I. INTRODUCTION

II. INDICATIONS

III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL

IV. SPECIFICATIONS OF THE EXAMINATION

V. DOCUMENTATION

VI. EQUIPMENT SPECIFICATIONS

VII. RADIATION SAFETY

VIII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION

ACKNOWLEDGEMENTS

REFERENCES

1. [-3197674] American College of Radiology. ACR–ACNM–SNMMI–SPR Practice Parameter for the Use of Radiopharmaceuticals in Diagnostic Procedures. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=171+&releaseId=2
2. [-3197669] American College of Radiology. ACR–ACNM–SNMMI–SPR Practice Parameter for Performing FDG-PET/CT in Oncology. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=173+&releaseId=2
3. [-3197668] American College of Radiology. ACR–ACNM–SNMMI Practice Parameter for the Performance of Gallium-68 and Copper-64 DOTATATE PET/CT Imaging for Neuroendocrine Tumors. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=18+&releaseId=2
4. [-3120926] American College of Radiology. ACR-SPR Practice Parameter for Imaging Pregnant or Potentially Pregnant Patients with Ionizing Radiation. Available at: https://gravitas.acr.org/PPTS/GetDocumentView?docId=23+&releaseId=2.
5. [20644928] Bombardieri E, Giammarile F, Aktolun C, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2436-46.
6. [11158063] Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001 Feb;86(2):895-902.
7. [3890187] McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med. 1985 Apr;15(2):132-53.
8. [12375024] Nakatani T, Hayama T, Uchida J, Nakamura K, Takemoto Y, Sugimura K. Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging. Oncol Rep. 2002;9(6):1225-7.
9. [12658506] Olivier P, Colarinha P, Fettich J, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging. 2003 May;30(5):B45-50.
10. [21803184] Sharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011 Sep;41(5):345-53.
11. [22926712] Taieb D, Timmers HJ, Hindie E, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 39(12):1977-95, 2012 Dec.
12. [-3197850] Biersack HJ, Freeman LM. Clinical Nuclear Medicine. New York, NY: Springer Medical Publishing; 2007.
13. [-3197765] GE Healthcare. Highlights of Prescribing Information: These highlights do not include all the information needed to use VIZAMYL safely and effectively. See full prescribing information for VIZAMYL. VIZAMYL (flutemetamol F 18 injection) for intravenous use. ; Initial U.S. Approval: 2013.
14. [21233182] Gelfand MJ, Parisi MT, Treves ST, Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med. 2011 Feb;52(2):318-22.
15. [24599377] Lassmann M, Treves ST, Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging. 2014 May;41(5):1036-41.
16. [19713709] Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. [46 refs]. Neuroendocrinology. 90(2):184-9, 2009.
17. [2170840] Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990 Nov 01;323(18):1246-9.
18. [9618580] Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med. 1998 Jun;25(6):639-58.
19. [20461371] Bombardieri E, Ambrosini V, Aktolun C, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1441-8.
20. [11965603] Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. [Review] [70 refs]. Semin Nucl Med. 32(2):84-91, 2002 Apr.
21. [-3197851] United States Nuclear Regulatory Commission. Nursing mother guidelines for the medical administration of radioactive materials. Available at: https://www.nrc.gov/docs/ML1817/ML18177A451.pdf. .
22. [11158032] van der Harst E, de Herder WW, Bruining HA, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001 Feb;86(2):685-93.
23. [21157198] Fukuoka M, Taki J, Mochizuki T, Kinuya S. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma. Clin Nucl Med. 36(1):1-7, 2011 Jan.
24. [19949879] Meyer-Rochow GY, Schembri GP, Benn DE, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol. 17(2):392-400, 2010 Feb.
25. [8790194] Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med. 1996 Sep;37(9):1464-8.
26. [-3197621] American College of Radiology. ACR Practice Parameter for Communication of Diagnostic Imaging Findings. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=74+&releaseId=2
27. [-3197885] American College of Radiology. ACR–AAPM Technical Standard for Nuclear Medical Physics Performance Monitoring of Gamma Cameras. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=196+&releaseId=2